<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Primary humoral immunodeficiencies: An overview</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Primary humoral immunodeficiencies: An overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Primary humoral immunodeficiencies: An overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ivan K Chinn, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan S Orange, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Inborn errors of immunity (IEI; previously "primary immunodeficiency diseases") encompass over 485 intrinsic defects of immunity, most of which are inheritable [<a href="#rid1">1</a>]. These conditions are classified into 10 main groups, including immunodeficiencies affecting cellular and humoral immunity; combined immunodeficiencies with associated or syndromic features; predominantly antibody deficiencies; diseases of immune dysregulation; congenital defects of phagocyte number, function, or both; defects in intrinsic and innate immunity; autoinflammatory disorders; complement deficiencies; bone marrow failure diseases; and phenocopies of IEI. (See  <a class="medical medical_review" href="/z/d/html/117758.html" rel="external">"Inborn errors of immunity (primary immunodeficiencies): Classification"</a>.)</p><p>Within this classification scheme, primary humoral immunodeficiencies are captured by the "predominantly antibody deficiencies" category. They are characterized by B cell-intrinsic abnormalities that classically result in decreased B cell numbers, impaired antibody production, or both. Because the defects are largely restricted to B cells, primary humoral immunodeficiencies are distinguished separately from other IEI in which abnormal B cell activity plays only a partial role in the disease manifestation. (See  <a class="medical medical_review" href="/z/d/html/3935.html" rel="external">"Combined immunodeficiencies: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PRESENTATION OF HUMORAL IMMUNODEFICIENCY</span><span class="headingEndMark"> — </span>The presence of an underlying primary humoral immunodeficiency should be suspected in a patient with typical sites of infections and types of infectious organisms isolated. Antibodies play an essential role in protection of the sinopulmonary tract and mucosal surfaces. Thus, affected persons commonly develop recurrent otitis media, sinusitis, and pneumonia. Recurrent pneumonias can lead to bronchiectasis, which serves as a negative factor for long-term morbidity and mortality [<a href="#rid2">2</a>]. Classic pathogens consist of polysaccharide-encapsulated bacteria, such as <em>Streptococcus pneumoniae</em> and <em>Haemophilus influenzae </em>[<a href="#rid3">3,4</a>]. Chronic diarrhea associated with <em>Giardia lamblia</em>, <em>Salmonella enterica</em>, <em>Campylobacter jejuni</em>, and rotavirus infections have been observed. Of note, infections are not limited to mucosal surfaces. Invasive infections, such as bacteremia, meningitis, osteomyelitis, and subacute infectious arthritis, can occur due to antibody deficiency and have been attributed to <em>Staphylococcus aureus</em>, <em>Pseudomonas aeruginosa</em>, and <em>Mycoplasma</em> species, in addition to the characteristic encapsulated bacteria [<a href="#rid3">3,4</a>]. Lastly, because of maternal transfer of immunoglobulin G (IgG) to the fetus in utero, a classic presentation for primary humoral immunodeficiency consists of an infant whose susceptibility to infections arises at four to nine months of age, when protective levels of the maternal antibodies have waned  (<a class="graphic graphic_figure graphicRef99496" href="/z/d/graphic/99496.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H2295781665"><span class="h1">ASSESSMENT OF HUMORAL IMMUNODEFICIENCY</span><span class="headingEndMark"> — </span>Several laboratory studies are recommended for evaluation of suspected primary humoral immunodeficiency (see  <a class="medical medical_review" href="/z/d/html/3903.html" rel="external">"Laboratory evaluation of the immune system"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Measurement of serum levels of IgG, immunoglobulin A (IgA), and immunoglobulin M (IgM) </strong>– The levels obtained must be compared with age-adjusted normal references ranges  (<a class="graphic graphic_table graphicRef107086" href="/z/d/graphic/107086.html" rel="external">table 1</a>). Interpretation of serum IgG levels during the first several months of life should take into consideration the presence or absence of maternal IgG.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment of functional antibody production </strong>– In general, this process entails the evaluation of specific antibody titers generated in response to protein and (in children above two years of age) polysaccharide vaccines. (See  <a class="medical medical_review" href="/z/d/html/3929.html" rel="external">"Assessing antibody function as part of an immunologic evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunophenotyping of B cells by flow cytometry</strong> – The absence of B cells or certain B cell subsets, such as marginal zone or switched memory B cells, can help to support the presence of underlying primary humoral immunodeficiency. (See  <a class="medical medical_review" href="/z/d/html/3937.html" rel="external">"Flow cytometry for the diagnosis of inborn errors of immunity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic testing</strong> – Over 45 genetic defects have been identified as causes of primary humoral immunodeficiencies [<a href="#rid1">1</a>]. Identification of a disease-causing molecular defect can confirm the presence of primary humoral immunodeficiency. Specific recommendations concerning testing choices remain beyond the scope of this discussion (see  <a class="medical medical_review" href="/z/d/html/116805.html" rel="external">"Genetic testing in patients with a suspected primary immunodeficiency or autoinflammatory syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/17039.html" rel="external">"Next-generation DNA sequencing (NGS): Principles and clinical applications"</a>), but broad testing may be necessary due to the significant locus heterogeneity for several of the primary humoral immunodeficiency phenotypes  (<a class="graphic graphic_table graphicRef139944" href="/z/d/graphic/139944.html" rel="external">table 2</a>).</p><p></p><p class="headingAnchor" id="H2518879690"><span class="h1">NEWBORN SCREENING</span><span class="headingEndMark"> — </span>Newborn screening for severe B cell deficiencies is also possible by measurement of kappa-deleting recombination excision circles (KRECs) levels in blood and in deoxyribonucleic acid (DNA) isolated from dried blood spots (DBS). KRECs are undetectable in inborn errors of immunity (IEI) in which B cells are absent or dysfunctional. This screening is under investigation in several countries and states in the US. (See  <a class="medical medical_review" href="/z/d/html/16363.html" rel="external">"Newborn screening for inborn errors of immunity", section on 'Screening for B cell defects'</a>.)</p><p class="headingAnchor" id="H2604524317"><span class="h1">CATEGORIES OF PRIMARY HUMORAL IMMUNODEFICIENCIES</span><span class="headingEndMark"> — </span>Primary humoral immunodeficiencies have been categorized into four groups by the International Union of Immunological Societies (IUIS)  (<a class="graphic graphic_table graphicRef139944" href="/z/d/graphic/139944.html" rel="external">table 2</a>) [<a href="#rid1">1</a>]. Gene-disease validity (the certainty for which a specific gene defect is causing a particular disease) can be reviewed on <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fsearch.clinicalgenome.org%2Fkb%2Fgene-validity%3Fpage%3D1%26size%3D25%26search%3D&amp;token=huArPlKmeyU9jfruBDESZpzVGXUEGhU8SnP3aiZDG3u%2BSgqeqGdoFrIGE%2F1Rtv4Vy7epDN9oAgDyiz%2FbtTmBrQUUleamBVC9qHE7jIXHcVk%3D&amp;TOPIC_ID=3914" target="_blank">the ClinGen website</a>.</p><p class="headingAnchor" id="H3938229044"><span class="h2">Agammaglobulinemia (severe reduction in all serum immunoglobulin isotypes with profoundly decreased or absent B cells)</span><span class="headingEndMark"> — </span>These conditions are identified by very low levels of serum IgG, IgA, and IgM with lack of B cells in the circulation  (<a class="graphic graphic_table graphicRef139944" href="/z/d/graphic/139944.html" rel="external">table 2</a>). They are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3931.html" rel="external">"Agammaglobulinemia"</a>.)</p><p class="headingAnchor" id="H2671967234"><span class="h2">CVID phenotype (severe reduction in at least two serum immunoglobulin isotypes with normal or low number of B cells)</span><span class="headingEndMark"> — </span>The diagnosis of common variable immunodeficiency disease (CVID) is established through fulfillment of specific criteria [<a href="#rid5">5</a>]. Affected individuals have low serum levels of IgG with diminished concentrations of IgA and/or IgM, poor specific antibody responses to immunizations, and deficient isohemagglutinins. Although B cells are present, switched memory B cell numbers and percentages may be low. Other immunodeficiency states must also be excluded. (See  <a class="medical medical_review" href="/z/d/html/3928.html" rel="external">"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults"</a> and  <a class="medical medical_review" href="/z/d/html/16132.html" rel="external">"Common variable immunodeficiency in children"</a>.)</p><p class="headingAnchor" id="H2490353563"><span class="h2">Hyper IgM (severe reduction in serum IgG and IgA with normal/elevated IgM and normal numbers of B cells)</span><span class="headingEndMark"> — </span>These primary humoral immunodeficiencies are often characterized by elevated serum levels of IgM (hyper IgM) accompanied by low levels of serum IgG and IgA. The underlying pathophysiology consists of impaired switching of B cells from the IgM isotype to the IgG and IgA isotypes due to defective DNA processing mechanisms. Of note, X-linked hyper-IgM syndrome due to pathogenic variants in the CD40 ligand (<em>CD40LG</em>) gene does not fall into this category since this condition has defects in cellular immunity that convey its placement into the category of combined immunodeficiency. The forms of hyper-IgM syndrome that do fit into this group include autosomal recessive pathogenic variants in activation-induced cytidine deaminase (<em>AICDA</em>) and uracil DNA glycosylase (<em>UNG</em>). Other class-switch recombination defects include pathogenic variants in mutS homolog 6 (<em>MSH6</em>) [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/13567.html" rel="external">"Hyperimmunoglobulin M syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a> and  <a class="medical medical_review" href="/z/d/html/13933.html" rel="external">"Normal B and T lymphocyte development", section on 'Maturation of activated B cells'</a>.)</p><p class="headingAnchor" id="H3973384400"><span class="h2">Isotype, light chain, or functional deficiencies with generally normal numbers of B cells</span><span class="headingEndMark"> — </span>A number of additional primary humoral immunodeficiency diagnoses have been observed. Most of these states are distinguished by abnormalities in immunoglobulin levels or specific antibody production and include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transient hypogammaglobulinemia of infancy (THI) </strong>– THI is classically defined as a delayed physiologic maturation of immunoglobulin production, which produces prolongation of the "physiologic nadir" of hypogammaglobulinemia that is observed in most normal infants at three to six months of age  (<a class="graphic graphic_figure graphicRef99496" href="/z/d/graphic/99496.html" rel="external">figure 1</a>). Infants with THI are able to generate protective specific antibody responses. Immunoglobulin levels normalize by three years of age in most children with THI, although serum immunoglobulin concentrations may remain diminished for several years in some children. (See  <a class="medical medical_review" href="/z/d/html/5951.html" rel="external">"Transient hypogammaglobulinemia of infancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selective IgA deficiency</strong> – Selective IgA deficiency, the most common immunologic defect in humans, is defined as the presence of serum IgA levels less than 7 mg/dL with normal IgG and IgM levels in individuals four years of age or older. [<a href="#rid7">7,8</a>]. The overwhelming majority of individuals with IgA deficiency are clinically asymptomatic. On occasion, recurrent infections of the respiratory tract or gastrointestinal tract can occur. (See  <a class="medical medical_review" href="/z/d/html/3963.html" rel="external">"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolated IgG subclass deficiency</strong> – IgG subclass deficiency is a laboratory finding that does not necessarily equate to a clinical disorder. The diagnosis of a clinically significant IgG subclass deficiency requires evidence of antibody dysfunction in the form of recurrent infections and an inadequate response to vaccine challenge. (See  <a class="medical medical_review" href="/z/d/html/3906.html" rel="external">"IgG subclass deficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IgG subclass deficiency with IgA deficiency</strong> – This condition is characterized by recurrent bacterial infections in the setting of both IgA and IgG subclass deficiency. (See  <a class="medical medical_review" href="/z/d/html/3963.html" rel="external">"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis", section on 'Patients with recurrent infections'</a> and  <a class="medical medical_review" href="/z/d/html/3906.html" rel="external">"IgG subclass deficiency", section on 'Associated disorders'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific antibody deficiency with normal immunoglobulin and B cell levels</strong> – Affected individuals usually have normal serum levels of IgG, IgA, and IgM and normal B cell numbers and percentages yet impaired antibody responses to specific antigens, such as immunizations. (See  <a class="medical medical_review" href="/z/d/html/3965.html" rel="external">"Specific antibody deficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunoglobulin deficiency due to immunoglobulin heavy chain constant region mu (</strong><strong><em>IGHM</em></strong><strong>) variants and deletions</strong> – This agammaglobulinemia (MIM #601495) is associated with genetic variations at 14q32 and is rare  (<a class="graphic graphic_table graphicRef139944" href="/z/d/graphic/139944.html" rel="external">table 2</a>) [<a href="#rid9">9-11</a>]. (See  <a class="medical medical_review" href="/z/d/html/3931.html" rel="external">"Agammaglobulinemia", section on 'Autosomal recessive agammaglobulinemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kappa chain deficiency</strong> – This condition is associated with autosomal recessive pathogenic variants in the immunoglobulin kappa constant (<em>IGKC</em>) gene (MIM #614102) [<a href="#rid12">12</a>]. As a result, deficiency of immunoglobulins carrying kappa chains arises. The clinical relevance of this finding remains controversial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selective IgM deficiency</strong> – This rare deficiency is associated with increased susceptibility to pneumococcal and other serious bacterial infections. (See  <a class="medical medical_review" href="/z/d/html/3921.html" rel="external">"Selective IgM deficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CARD11 GOF/BENTA syndrome </strong>– Autosomal dominant pathogenic variants in caspase recruitment domain family member 11 (<em>CARD11</em>) cause a gain-of-function (GOF) variant that results in B cell expansion with nuclear factor kappa B and T cell anergy (BENTA) syndrome (MIM #616452) [<a href="#rid13">13,14</a>]. This disease condition is characterized by polyclonal expansion of B cells. However, specific antibody responses are impaired, resulting in humoral immunodeficiency. Loss-of-function (LOF) pathogenic variants in <em>CARD11</em> cause a combined immunodeficiency and are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/141326.html" rel="external">"Combined immunodeficiencies: Specific defects", section on 'CARD11 deficiency'</a>.)</p><p></p><p class="headingAnchor" id="H21446846"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Humoral defects can appear in other inborn errors of immunity (IEI) that are not restricted to B cells, such as combined immunodeficiencies (see  <a class="medical medical_review" href="/z/d/html/3935.html" rel="external">"Combined immunodeficiencies: An overview"</a>). Patients with humoral immunodeficiency must therefore be assessed for defects in other immune functions, such as cellular and innate immunity. Secondary causes of humoral immunodeficiency must also be excluded, including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – Antiseizure medications, such as <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, and <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a>, are well-recognized causes of IgA deficiency [<a href="#rid15">15</a>]. Use of antiinflammatory drugs (eg, gold, <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a>, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, and <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>) is associated with hypogammaglobulinemia [<a href="#rid16">16</a>]. In addition, many immunosuppressive medications, including <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, and <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">6-mercaptopurine</a>, can cause hypogammaglobulinemia. Glucocorticoids may induce hypogammaglobulinemia when administered for extended periods of time [<a href="#rid16">16</a>] (see  <a class="medical medical_review" href="/z/d/html/3986.html" rel="external">"Glucocorticoid effects on the immune system"</a>). Finally, several targeted biologic therapies (eg, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and anti-CD19 chimeric antigen receptor T cells) are intended to cause depletion of B cells and can result in hypogammaglobulinemia. (See  <a class="medical medical_review" href="/z/d/html/3939.html" rel="external">"Secondary immunodeficiency induced by biologic therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Losses</strong> – Pulmonary losses can occur through the presence of a chylothorax or exudative pleural effusion due to either obstructed lymphatic flow or perturbed intrathoracic pressure. Gastrointestinal losses, due to protein-losing enteropathies such intestinal lymphangiectasia, must be excluded. Nephrotic syndrome can also produce hypogammaglobulinemia through urinary losses. In addition, protein loss can occur with severe atopic dermatitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malnutrition</strong> – Poor nutritional status may represent the most common cause of immunodeficiency worldwide, and severe malnutrition is known to result in decreased production of secretory IgA and diminished numbers of B cells [<a href="#rid17">17,18</a>]. Immune function returns to normal when proper nutritional balance is restored.</p><p></p><p class="headingAnchor" id="H2048869491"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">Immune globulin</a> replacement therapy is indicated for primary humoral immunodeficiencies that consist of absent or deficient antibody production [<a href="#rid19">19</a>] (see  <a class="medical medical_review" href="/z/d/html/3911.html" rel="external">"Immune globulin therapy in inborn errors of immunity"</a>). Recommended use of immune globulin replacement therapy is dictated by placement of the condition within one of six categories:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agammaglobulinemia due to complete absence of B cells or B cell function</strong> – This category matches the International Union of Immunological Societies (IUIS) primary humoral immunodeficiency subcategory of "severe reduction in all serum immunoglobulin isotypes with profoundly decreased or absent B cells, agammaglobulinemia" and includes all of the diagnoses contained within it. <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">Immune globulin</a> replacement therapy is fully indicated for these defects due to the severe reduction in all serum immunoglobulin isotypes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypogammaglobulinemia with impaired specific antibody production</strong> – The IUIS primary humoral immunodeficiency subcategories of "severe reduction in at least two serum immunoglobulin isotypes with normal or low number of B cells, common variable immunodeficiency (CVID) phenotype" and "severe reduction in serum IgG and IgA with normal/elevated IgM and normal numbers of B cells, variable immunoglobulin findings" fall into this designation. <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">Immune globulin</a> replacement therapy is advised for this category as well since patients have a severe reduction in at least two serum immunoglobulin isotypes in CVID and in IgG and IgA in class-switch recombination defects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal levels of immunoglobulin and normal B cells but impaired specific antibody production</strong> – This category falls within the IUIS primary humoral immunodeficiency subcategory of "isotype, light chain, or functional deficiencies with generally normal numbers of B cells." <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">Immune globulin</a> replacement therapy is not generally recommended as initial treatment for these conditions but may be used if the antibody deficiency is more severe. More often, patients are treated with antibiotic prophylaxis [<a href="#rid20">20-23</a>]. (See  <a class="medical medical_review" href="/z/d/html/3948.html" rel="external">"Inborn errors of immunity (primary immunodeficiencies): Overview of management", section on 'Prophylactic antimicrobial therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypogammaglobulinemia and normal-quality antibody responses</strong> – Transient hypogammaglobulinemia of infancy (THI) also falls within the IUIS primary humoral immunodeficiency subcategory of "isotype, light chain, or functional deficiencies with generally normal numbers of B cells." <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">Immune globulin</a> replacement therapy is not generally recommended for conditions within this category.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal serum IgG levels, normal-quality antibody responses, and decreased serum level of one or more IgG subclasses</strong> – The IgG subclass deficiencies also fall within the IUIS primary humoral immunodeficiency subcategory of "isotype, light chain, or functional deficiencies with generally normal numbers of B cells." Guidelines do not recommend IgG replacement therapy for these diagnoses, but the restriction remains controversial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent infections due to an unknown immune mechanism –</strong> This category does not apply to primary humoral immunodeficiencies, since all primary humoral immunodeficiencies fall into one of the other five categories.</p><p></p><p class="headingAnchor" id="H1492365312"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112831.html" rel="external">"Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"</a>.)</p><p class="headingAnchor" id="H14368569"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Primary humoral immunodeficiencies  (<a class="graphic graphic_table graphicRef139944" href="/z/d/graphic/139944.html" rel="external">table 2</a>) are recognized as predominantly antibody deficiencies that are distinguished separately from other inborn errors of immunity (IEI) in which humoral abnormalities play only a partial role in the disease manifestation. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation</strong> – Antibody deficiency classically presents with recurrent infections of the sinopulmonary tract by polysaccharide-encapsulated pathogens, such as <em>Streptococcus pneumoniae</em> and <em>Haemophilus influenzae</em>. Chronic infectious diarrhea and invasive infections can also occur. The classic age at presentation is four to nine months. (See <a class="local">'Presentation of humoral immunodeficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – Persons with suspected primary humoral immunodeficiencies should be evaluated by measurements of serum immunoglobulin levels, assessment of antibody responses to specific antigens, characterization of B cell phenotypes by flow cytometry, and (in some cases) genetic testing. (See <a class="local">'Assessment of humoral immunodeficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – In order to establish a diagnosis of primary humoral immunodeficiency, other IEI and secondary causes of humoral immunodeficiency must be excluded. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">Immune globulin</a> replacement therapy is indicated for most primary humoral immunodeficiencies in accordance with recommendations from expert guidelines. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/z/d/html/3911.html" rel="external">"Immune globulin therapy in inborn errors of immunity"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; 42:1473.</a></li><li><a class="nounderline abstract_t">Gathmann B, Mahlaoui N, CEREDIH, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol 2014; 134:116.</a></li><li><a class="nounderline abstract_t">Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 2006; 85:193.</a></li><li><a class="nounderline abstract_t">Oksenhendler E, Gérard L, Fieschi C, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 2008; 46:1547.</a></li><li><a class="nounderline abstract_t">Ameratunga R, Brewerton M, Slade C, et al. Comparison of diagnostic criteria for common variable immunodeficiency disorder. Front Immunol 2014; 5:415.</a></li><li><a class="nounderline abstract_t">Gardès P, Forveille M, Alyanakian MA, et al. Human MSH6 deficiency is associated with impaired antibody maturation. J Immunol 2012; 188:2023.</a></li><li><a class="nounderline abstract_t">Wang N, Hammarström L. IgA deficiency:  what is new? Curr Opin Allergy Clin Immunol 2012; 12:602.</a></li><li><a class="nounderline abstract_t">Singh K, Chang C, Gershwin ME. IgA deficiency and autoimmunity. Autoimmun Rev 2014; 13:163.</a></li><li><a class="nounderline abstract_t">Conley ME, Sweinberg SK. Females with a disorder phenotypically identical to X-linked agammaglobulinemia. J Clin Immunol 1992; 12:139.</a></li><li><a class="nounderline abstract_t">Yel L, Minegishi Y, Coustan-Smith E, et al. Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N Engl J Med 1996; 335:1486.</a></li><li><a class="nounderline abstract_t">Lopez Granados E, Porpiglia AS, Hogan MB, et al. Clinical and molecular analysis of patients with defects in micro heavy chain gene. J Clin Invest 2002; 110:1029.</a></li><li><a class="nounderline abstract_t">Zegers BJ, Maertzdorf WJ, Van Loghem E, et al. Kappa-chain deficiency. An immunoglobulin disorder. N Engl J Med 1976; 294:1026.</a></li><li><a class="nounderline abstract_t">Brohl AS, Stinson JR, Su HC, et al. Germline CARD11 Mutation in a Patient with Severe Congenital B Cell Lymphocytosis. J Clin Immunol 2015; 35:32.</a></li><li><a class="nounderline abstract_t">Snow AL, Xiao W, Stinson JR, et al. Congenital B cell lymphocytosis explained by novel germline CARD11 mutations. J Exp Med 2012; 209:2247.</a></li><li><a class="nounderline abstract_t">Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol 2015; 136:1186.</a></li><li><a class="nounderline abstract_t">Dhalla F, Misbah SA. Secondary antibody deficiencies. Curr Opin Allergy Clin Immunol 2015; 15:505.</a></li><li><a class="nounderline abstract_t">Rytter MJ, Kolte L, Briend A, et al. The immune system in children with malnutrition--a systematic review. PLoS One 2014; 9:e105017.</a></li><li><a class="nounderline abstract_t">Bourke CD, Berkley JA, Prendergast AJ. Immune Dysfunction as a Cause and Consequence of Malnutrition. Trends Immunol 2016.</a></li><li><a class="nounderline abstract_t">Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol 2017; 139:S1.</a></li><li><a class="nounderline abstract_t">Perez E, Bonilla FA, Orange JS, Ballow M. Specific Antibody Deficiency: Controversies in Diagnosis and Management. Front Immunol 2017; 8:586.</a></li><li><a class="nounderline abstract_t">Joud Hajjar, Nguyen AL, Constantine G, et al. Prophylactic Antibiotics Versus Immunoglobulin Replacement in Specific Antibody Deficiency. J Clin Immunol 2020; 40:158.</a></li><li><a class="nounderline abstract_t">Perez EE, Ballow M. Diagnosis and management of Specific Antibody Deficiency. Immunol Allergy Clin North Am 2020; 40:499.</a></li><li><a class="nounderline abstract_t">Smits BM, Kleine Budde I, de Vries E, et al. Immunoglobulin Replacement Therapy Versus Antibiotic Prophylaxis as Treatment for Incomplete Primary Antibody Deficiency. J Clin Immunol 2021; 41:382.</a></li></ol></div><div id="topicVersionRevision">Topic 3914 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35748970" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24582312" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical picture and treatment of 2212 patients with common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16862044" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : X-linked agammaglobulinemia: report on a United States registry of 201 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419489" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Infections in 252 patients with common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25309532" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparison of diagnostic criteria for common variable immunodeficiency disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22250089" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Human MSH6 deficiency is associated with impaired antibody maturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23026772" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : IgA deficiency:  what is new?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24157629" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : IgA deficiency and autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1560108" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Females with a disorder phenotypically identical to X-linked agammaglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8890099" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mutations in the mu heavy-chain gene in patients with agammaglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12370281" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical and molecular analysis of patients with defects in micro heavy chain gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/815819" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Kappa-chain deficiency. An immunoglobulin disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25352053" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Germline CARD11 Mutation in a Patient with Severe Congenital B Cell Lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23129749" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Congenital B cell lymphocytosis explained by novel germline CARD11 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26371839" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Practice parameter for the diagnosis and management of primary immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26406183" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Secondary antibody deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25153531" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The immune system in children with malnutrition--a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27237815" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Immune Dysfunction as a Cause and Consequence of Malnutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28041678" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Update on the use of immunoglobulin in human disease: A review of evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28588580" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Specific Antibody Deficiency: Controversies in Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31758281" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prophylactic Antibiotics Versus Immunoglobulin Replacement in Specific Antibody Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32654695" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Diagnosis and management of Specific Antibody Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33206257" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Immunoglobulin Replacement Therapy Versus Antibiotic Prophylaxis as Treatment for Incomplete Primary Antibody Deficiency.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
